Polaryx CFO Buys Shares Amid FDA “Safe to Proceed” Letter, Signaling Potential Upside for PLX‑200
Polaryx CFO’s insider buy signals confidence amid FDA “safe‑to‑proceed” letter and Phase‑2 trial; could boost value if PLX‑200 shows early efficacy.
4 minutes to read